

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Declerck *et al.* Examiner: To be assigned
Serial No.: 10/757,857 Group Art Unit: To be assigned
Filed: January 14, 2004
For: "System for Controlling Medical Data Acquisition Processes"
Customer No.: 23719

Kalow & Springut LLP
488 Madison Avenue, 19th Floor
New York, New York 10022

May 13, 2004

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL OF PRIORITY DOCUMENT

Sir:

Enclosed is a copy of the certified priority document for the above-identified application.

If there are any questions regarding this matter, the Examiner is respectfully invited to contact the Applicants' attorney at the telephone number given below. Thank you for your time and attention to this matter.

Respectfully submitted,

Scott D. Locke, Esq.
Registration No.: 44,877
Attorney for Applicant

Kalow & Springut LLP
(212) 813-1600

Certificate of Mailing Under 37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited on the date shown below with the United States Postal Service as first class mail with sufficient postage in an envelope addressed to: MS Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

(Signature)

K Padilla

(Printed Name of Person Signing
Certificate)

5/13/04

(Date)



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

H. Behan

Dated 19 April 2004





1/77
16 JAN 03 1777352-6 000192
P01/7700 0.00-0300922.2

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office


Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference	N.87368 MN		
2. Patent application number (The Patent Office will fill in this part)	0300922.2		
3. Full name, address and postcode of the or of each applicant (underline all surnames)	MIRADA SOLUTIONS LIMITED Oxford Centre for Innovation Mill Street Oxford OX2 0JX United Kingdom		
Patents ADP number (if you know it)			
If the applicant is a corporate body, give the country/state of its incorporation	GB	8429375002	
4. Title of the invention	SYSTEM FOR CONTROLLING MEDICAL DATA ACQUISITION PROCESSES		
5. Name of your agent (if you have one)	J.A. KEMP & CO.		
"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)	14 South Square Gray's Inn London WC1R 5JJ		
Patents ADP number (if you know it)	26001		
6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of filing (day / month / year)
7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application		Date of filing (day / month / year)
8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if: a) any applicant named in part 3 is not an inventor, or b) there is an inventor who is not named as an applicant, or c) any named applicant is a corporate body. See note (d))	Yes		

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form

Description	10
Claim(s)	2
Abstract	1
Drawing(s)	5 + 5 

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77) 1

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature


J.A. KEMP & CO.

Date 15 January 2003

12. Name and daytime telephone number of person to contact in the United Kingdom

NICHOLLS, Michael John
020 7405 3292

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

SYSTEM FOR CONTROLLING MEDICAL
DATA ACQUISITION PROCESSES

5 The present invention relates to a system for controlling the acquisition of medical data, in particular to provide for the possibility of improved medical data acquisition protocols.

The acquisition of medical data such as image or spectroscopy data is an important part of modern medical practice. As diagnostic imaging (medical imaging) with technologies such as Magnetic Resonance Imaging (MRI), Computed
10 Tomography (CT) and Positron Emission Tomography (PET) increase in spatial resolution, acquisition speed and clinical flexibility, sophisticated diagnostic techniques involving the injection of imaging agents to characterise very specific physiological and pathophysiological indicators have evolved. This concept extends from very basic contrast agents (for example, iodine blood pool agents that increase
15 the x-ray attenuation of a CT scan and hence improve the contrast blood vessels) to the new fields known as "molecular imaging" and "functional imaging".

Molecular imaging (MI) and functional imaging (FI) are revolutionary because imaging agents can be used which target very specific biophysical, cellular or genetic behaviour. It is possible to screen for a specific disease by attaching a
20 gene to an imaging agent that only makes the compound visible during medical imaging if a particular disease (e.g. oncogene) is present. This notion extends to a vast range of applications from oncology to cardiology and neuroimaging for diseases such as Parkinson's and Alzheimer's syndromes.

Given that molecular imaging (which can be broadly generalised to
25 "functional imaging") can accurately characterise a disease state, it can also accurately characterise treatment response to surgery, chemotherapy (including gene therapy, stem cell therapy) and radiotherapy. However in order to benefit fully from such functional imaging techniques it would be advantageous to achieve the control and measurement of delivery of the imaging agent. Even slight variations in the
30 injection profile or inhalation of a highly sophisticated imaging agent can alter the

measured value of the indicated [patho]physiology. This is important calibration information for the analysis of the imaging process.

Currently some devices exist to control and trigger drug delivery and image acquisition. This is illustrated in Figure 1 of the accompanying drawings. A medical data acquisition device 1, in this case an imaging device, is operable to provide
5 images of a subject 3, in this case a human patient. During the image acquisition process a drug delivery device 5 is used to administer a contrast agent to the patient and the drug delivery and image acquisition are synchronised in accordance with a predefined acquisition protocol under control of a computer-based control system 7.
10 Conventionally the patient's condition may be monitored (such as blood pressure, ECG etc) by an additional patient monitoring device schematically illustrated as 9. A human operator of the system may abort the acquisition protocol if the patient monitoring device 9 shows an undesirable change in the patient's condition.

However, this conventional type of system can only put into practice a set,
15 pre-defined acquisition protocol. The only way of adapting the protocol is in response to the human assessment of the patient's condition. With many acquisition techniques this can cause problems because the timing of the image acquisition should be responsive to the behaviour of the agent in the subject, rather than simply to the timing of the command to the drug delivery device.

20 Similar problems arise in other medical data acquisition techniques such as spectroscopy (e.g. magnetic resonance spectroscopy).

According to the present invention there is provided a system for controlling medical data acquisition process, comprising a data acquisition apparatus controller for controlling data acquisition apparatus to acquire medical data from a subject;
25 an agent administration controller for controlling a device to administer an agent to the subject;
a medical data processor for receiving the medical data from the data acquisition apparatus and processing it;
a protocol controller for controlling the data acquisition apparatus controller and
30 the agent administration controller in response to processed medical data results from

the medical data processor.

Preferably the data is processed in "real time", i.e. as it arrives, or within a short time compared to the timing of the whole procedure, so that "real time" control of the data acquisition apparatus based on the processed results is then possible.

5 Thus the present invention allows synchronisation of the agent administration (such as an imaging agent, e.g. contrast agent) with the results of the data acquisition itself (e.g. the image being acquired). This allows a much closer control of the acquisition protocol.

10 The device for administering the agent may be an automatic drug delivery device, and the agent may be a pharmaceutical agent, such as dobutamine for stress heart imaging, or an imaging agent, such as a contrast agent, in the case of medical imaging.

15 The protocol controller may control the relative timing of agent administration and data acquisition, may control the type and amount of agent administered so that, for example, more than one type of agent may be administered at different times through the protocol, and may control the data acquisition apparatus to switch between different data acquisition modes (for instance to collect different types of data at different times during the protocol).

20 The protocol controller may also be responsive to additional data acquired from the subject independently of the medical data acquisition apparatus. For example, in the case of a human or animal subject this may be in response to patient movement, blood pressure, heart rate variation etc. In particular, to successfully acquire medical images, particularly for moving organs, it is sometimes necessary to include physiological measurements of the patient, such as heart rate/characteristics,
25 respiratory information, motion etc. In one specific case this could be as simple as recording head movement during an MR scan, which movement introduces artefacts in the image, which could be confused with disease. The protocol controller can, for example, suspend image acquisition temporarily during a period of patient movement, thus adapting the protocol in real time.

30 The system is applicable both to the acquisition of medical data *in vivo*, e.g.

from a human, animal or plant subject, and *in vitro*, e.g. from medical samples. It is applicable to both dynamic studies, i.e. the use of medical imaging to characterise the physiological or pathophysiological behaviour as a function of time. Often this is performed in conjunction with an *in vivo* imaging agent which has specific
5 biophysical or pharmacokinetic behaviour. The invention is also applicable to pharmacokinetics, i.e. the biophysical characterisation of a molecule, compound, gene etc in or from the body.

The invention allows the synchronisation of the agent delivery and data acquisition, including baseline acquisition and delays between the delivery of the
10 agent, its delivery profile and the commencement of acquisition. Additionally, with knowledge (e.g. a model) of an agent's behaviour in the subject, it is possible to optimise the way in which the acquisition process is conducted with respect to the subject, for example in the case of a human or animal, in response to the height, weight, cardiac throughput of the subject, or the characteristics of the data acquisition
15 apparatus itself. This can give a better managed acquisition, better image quality, an optimised tradeoff between spatial and temporal resolution and, in certain cases (for example, with CT) minimisation of radiation dosed to the patient.

Synchronisation of the analysis of the data acquisition with the agent delivery allows critical timing information to be obtained to optimise the information
20 produced by the interaction between the agent and the physiological phenomenon under investigation. Further, real time analysis of the behaviour of the agent can be used to alter the acquisition sequence in order further to improve the acquisition result, reduce false positives, negatives, artefacts, and to calibrate the analysis of the agent against fluctuations in other measured parameters of subject, such as blood
25 pressure, respiration rate etc in a human or animal.

The invention will be further described by way of example with reference to the accompanying drawings in which:-

Figure 1 illustrates a prior art medical data acquisition system;

Figure 2 illustrates a medical data acquisition system in accordance with one
30 embodiment of the present invention;

Figure 3 illustrates the critical process timings in an image acquisition process for liver CT imaging in accordance with an embodiment of the present invention;

Figures 4(a) to (f) illustrate a frame sequence showing the change in intensity with time in a Gadolinium enhanced MRI scan; and

Figure 5 illustrates the change in intensity of a given voxel over time in a typical Gadolinium enhanced MRI scan.

Figure 2 illustrates a control system in accordance with the present invention applied to the imaging apparatus described above with reference to Figure 1. The parts found in Figure 1 are labelled with the same reference numerals and thus include the imaging device 1, the subject 2, the drug delivery device 5, the control system 7 and the additional patient monitor 9. In accordance with the present invention, though, the acquisition device 1 and agent administering device 5 are controlled, via the control system 7, by a supervisory control system 11. While this is shown separately from the control system 7 in Figure 2, the two may be combined. The supervisory control system 11 receives data from the imaging device and also from the additional patient monitor 9 and controls the drug delivery device 5 and imaging device 1 in real time in response to this image data and additional data from the monitoring device 9. Thus the supervisory control device 9 connects the imaging agent (drug) delivery mechanism 5, the imaging process, the acquisition of physiological parameters from the patient via monitoring device 9 and the analysis of the behaviour of the imaging agent for the purposes of diagnosis. It is illustrated in Figure 2 as being embodied in a general purpose personal computer, i.e. as a single integrated software system, though it can be embodied as a distributed set of software tools across the control system 7, drug delivery device 5, imaging device 1 and patient monitor 9. The supervisory controller 11 is effective via the control system 7 to control both the relative timings of drug delivery and image acquisition, and the type of drug (e.g. contrast agent) delivered and the mode of data acquisition. Thus multiple imaging agents may be administered with a desired administration profile, and the imaging device may be controlled accordingly, possible to switch modes in

accordance with the different agents administered.

Two different specific examples of the type of control made possible by the present invention will now be described.

5 1) CT Imaging of the Liver

Conventionally, liver tumours are assessed with CT images enhanced with contrast agents. The agent is used to create contrast between vascularisation and the tissue itself. The objective of the diagnostic based on such images is two-fold:

- 1) detection and assessment of liver tumours. Tumours are characterised by
10 lower contrast compared to the surrounding healthy tissue when the contrast agent washes in through the portal vein. Some other imaging modality like PET can be used to differentiate cancerous tumours from cysts or necrosis and degeneration from cirrhotic diseases, for instance. The main use of the CT image is to determine the location and extent of the tumours.
- 15 2) visualisation of the vascularisation of great vessels for surgery planning. When surgery is planned for the resection of the tumours, great care must be taken to remove the minimum amount of liver. The clinician uses the vascularisation tree to determine the region to remove.

The selection of the resection region is a complex process: in clinical
20 procedures, the liver is decomposed into 8 different segments, where boundaries are based on anatomical landmarks (Lafortune et al., "*Segmental anatomy of the liver: a sonographic approach to the Couinaud nomenclature*": Radiology 181(2):443-448, 1991). Other approaches enhance the precision of the definition of these boundaries using the portal vein instead of external shape-based landmarks (L. Soler, H.
25 Delingette, G. Malandain, J. Montagnat, N. Ayache, C. Koehl, O. Dourthe, B. Malassagne, M. Smith, D. Mutter and J. Marescaux: "Fully automatic anatomical, pathological, and functional segmentation from CT scans for hepatic surgery", Computer Aided Surgery, vol. 6, num. 3, August 2001). Basing the segmentation of liver on vascular tree is absolutely key for surgery planning, as the vascularisation of
30 the liver is one of the most complex of the whole human body. There are so many

blood vessels that a cut must minimise bleeding. Cutting through a great vessel is simple, as bleeding is easily controlled with clamping. Cutting through capillaries is simple as well, as cauterisation stops bleeding. But cutting at random in the liver can cause the rupture of many intermediate sized vessels, which cannot be cauterised
5 because they are too big, and for which clamping is not practical because hundreds of such vessels could be opened in one single cut.

Identification of the segments based on vascularisation is a more and more clinically accepted practice, but it needs good vascular tree segmentation. Such segmentation can be obtained for instance using CT imaging as illustrated in Figure
10 3. In a normal CT scan, the portal tree is not visible nor differentiable from surrounding liver cells, so the use of a contrast agent is necessary. Following a classic imaging protocol, the CT image is acquired very quickly after some contrast agent has been delivered into the patient's blood. The contrast agent is injected in a single bolus (t_0), and after a small period of time (t_1 , which is called *portal time*), the
15 bolus reaches the portal vein 30, one of the main vascular trees irrigating the liver. The contrast agent washes into the liver and enhances all vascular branches, until it reaches the capillaries (t_2). Then, contrast agent washes in all cells and other artery trees before flowing out in the vena cava (t_3). By this time, the whole liver is brightened by the contrast agent and the portal tree is no longer visible.

20 There are two main difficulties in the acquisition of a good and usable image:

1) The image needs to be acquired at t_2 , and not at t_1 or t_3 . The problem is that the margin $t_3 - t_1$ is very small, typically 5 or 10 seconds, so the image must be acquired very quickly.

2) The portal time needs to be estimated but cannot be determined a priori
25 with accuracy. Usually, $t_1 - t_0$ is between 10 and 20 seconds. If the portal time t_1 is not estimated correctly, the image is unusable, either too dark, or too bright, with no contrasting vascular tree.

So the evaluation of the exact portal time, i.e. time point t_1 , is the key to triggering the start of the imaging procedure. With the present invention the protocol
30 controller receives the data from the image acquisition apparatus and so is

programmed to look for the arrival of contrast agent at the entrance 30 to the portal vein. On detection on the image of contrast agent at the portal vein the time point t_1 is established with certainty. Thus rather than estimating the time for contrast agent to arrive from the drug delivery device to the portal vein (which could be about 20
5 seconds), its exact arrival at the entrance to the portal vein is detected. Then an image acquisition protocol for obtaining different slice images through the liver can be started to cover the short time period, for example 5 to 10 seconds, between times t_1 and t_3 . Automatic detection of the arrival of the contrast agent at the portal vein is achieved, for example, by the clinician first determining the location of the entrance
10 of the portal vein in a CT "scout" image used for setting a region of interest for the 3D image acquisition. The scanner then acquires at regular time intervals (e.g. every 2 or 3 seconds) an image of the area, and compares each image with the preceding one. The arrival of contrast agent shows up easily as a bright area on the previously uniformly grey vessel.

15

MR Imaging of the Breast

An example based on an optimised contrast-enhanced magnetic resonance image of the breast will now be described.

Figures 4 and 5 illustrate the typical dependency of contrast enhanced
20 intensity against time using Gadolinium (Gd) as a contrast agent. Figure 4 illustrates six frames of the sequence and Figure 5 shows a graph of the intensity of a given voxel. It can be seen that the intensity arises quite steeply over the first one or two minutes, e.g. through images (a), (b) and (c), and then decays very gradually, little change occurring from images (c) through (f). In order to accurately characterise the
25 nature of the material being enhanced it is necessary to detect the shape of this curve as accurately as possible. In particular, for example, it is important to be able to detect the peak intensity. Rather than following an acquisition protocol based on estimated behaviour, which may be based on some particular tissue type (or some average) the present invention allows different image acquisition modalities to be
30 used during different times in the protocol. For example:-

1) The supervisory control system 11 invokes a "baseline" (pre-injection) image acquisition along with calibration images for various physics-based corrections. For example, the paper Armitage P.A., Behrenbruch C.P., Brady, J.M. and Moore N. "Optimising flip-angles for improved T1 calculation in 3D contrast-enhanced breast MR imaging" in Proc. International Society of Magnetic Resonance in Medicine 2001 p. 526, describes a protocol to acquire images to compute a T1 map, which is characteristic of the tissue. (There are two reasons why a contrast agent shows a bright spot in MRI: (a) the T1 of the tissue is high, and becomes higher when the high-T1 contrast agent washes in, and (b) the tissue has an average T1, but there is a lot of contrast agent washing in. The difference is (a) is indicative of tissue that is definitely benign and normal, whereas (b) could be indicative of the trace of malignant tumour. Basically, when looking at the post-contrast image, there is no way to be able to quantitate how much of the brightening effect comes from the contrast agent and how much comes from the tissue. Obtaining a T1 map prior to the acquisition allows correction of the enhancement map for these artefacts.)

2) It then commands the delivery device 5 to inject Gadolinium (Gd) in a controlled bolus injection profile to be imaged in step (3) and characterised as an arterial input function in preparation for analysis.

3) The supervisory control system 11 immediately switches the MRI system 1 to a rapid echoplaner (EPI sequence) which performs a low spatial, high temporal resolution image (1 second acquisition) of the region of interest in the breast (or, in other examples, different parts of the body, e.g. the brain) until the measured contrast-induced (Gd) signal intensity in the imaging process reaches 100% of baseline. This period is critical for characterising regions of angiogenesis indicated by the uptake of gadolinium.

4) The supervisory control system 11 then switches the acquisition profile of the MRI system 1 to a slower, high-resolution gradient echo (e.g. Fast SPoiled GRAdient echo pulse sequence - FSPGR) sequence that acquires high quality 3D volumes to measure the plateau of contrast agent behaviour. Simultaneously, a smaller steady infusion of Gd is added via the delivery device 5 to buffer the peak

contrast.

5) A series of FSPGR sequences are acquired until the washout is sufficiently characterised to end acquisition. At the point where the analysis tools have all the pharmacokinetic parameters needed, acquisition is ceased.

5 6) The user is presented with a finalised analysis of the MRI data showing accurately parameterised areas of uptake which statistically correspond to regions indicative of tumour angiogenesis. This result is optimised as the analysis tool was "in time" to detect different phases of the contrast agent's biophysical behaviour (including injection profile) which in turn controlled infusion of Gd and the
10 acquisition protocol.

The invention can also accept data input from other sources, such as a heart rate monitor 9. Thus, for example, if midway through the acquisition the patient experiences some anxiety, as detected by an increase in cardiac activity, and moves, the supervisory protocol controller 11 can suspend acquisition, optionally motion
15 correct to the new patient geometry (e.g. using the technique described in WO 00/57361 herein incorporated by reference) and continue with the acquisition process.

Although the invention has been described above with respect to specific imaging techniques, it is applicable to other imaging and data acquisition techniques
20 including the use of: medical imaging by devices such as CT/MRI/PET/SPECT/X-ray/ Ultrasound/Optical, functional imaging, dynamic imaging, imaging with radiopharmaceuticals, contrast agents, hyperpolarised gases, x-ray attenuation agents, genetic/oncogenic markers, cellular/receptor level indicators, blood pool/flow agents and combined targeted imaging agents/targeted therapy agents.

25 The invention may be embodied in a computer program which, when executed on a general purpose computer, controls the data acquisition and agent administering device. Alternatively it may be embodied in firmware, programmable logic or dedicated process controls and automation systems.

CLAIMS

1. A system for controlling medical data acquisition process, comprising a data acquisition apparatus controller for controlling data acquisition apparatus to
5 acquire medical data from a subject;

an agent administration controller for controlling a device to administer an agent to the subject;

a medical data processor for receiving the medical data from the data acquisition apparatus and processing it;

10 a protocol controller for controlling the data acquisition apparatus controller and the agent administration controller in response to processed medical data results from the medical data processor.

2. A system according to claim 1 wherein the device to administer an agent
15 to the subject is an automatic drug delivery device.

3. A system according to claim 1 or 2 wherein the agent is a pharmaceutical agent.

20 4. A system according to claim 1, 2 or 3 wherein the agent is an imaging agent, the data acquisition apparatus is an imaging apparatus and the medical data processor is an image processor.

5. A system according to claim 4 wherein the imaging agent is a contrast
25 agent for selectively enhancing the contrast of at least one region of the subject.

6. A system according to any one of the preceding claims wherein the data acquisition apparatus is a spectroscopy apparatus and the medical data processor is a spectral data processor for processing data acquired by the spectroscopy apparatus.

7. A system according to any one of the preceding claims wherein the protocol controller controls the relative timing of data acquisition and agent administration, via the data acquisition apparatus controller and the agent administration controller respectively, in response to processed medical data results from the medical data processor.

8. A system according to any one of the preceding claims wherein the protocol controller controls the agent administration controller to control the amount of agent administered to the subject in response to processed medical data results from the medical data processor.

9. A system according to any one of the preceding claims wherein the protocol controller controls the agent administration controller to control the type of agent administered to the subject in response to processed medical data results from the medical data processor.

10. A system according to any one of the preceding claims wherein the protocol controller controls the data acquisition apparatus controller to control the mode of data acquisition to acquire data in at least two different modes in response to processed medical data results from the medical data processor.

11. A system according to any one of the preceding claims wherein the protocol controller is responsive to additional data acquired from the subject independently of the medical data acquisition apparatus.

12. A system according to any one of the preceding claims wherein the medical data is acquired *in vivo* from a human, animal or plant as said subject.

13. A system according to any one of claims 1 to 11 wherein the medical data is acquired *in vitro*.

ABSTRACT
SYSTEM FOR CONTROLLING MEDICAL
DATA ACQUISITION PROCESSES

5 A system for controlling medical data acquisition, such as imaging, comprises a
- supervisory protocol controller which controls in real time a data acquisition device,
such as an imaging apparatus, and an agent administration controller, such as a drug
delivery device for delivering contrast agent. The supervisory protocol controller
receives data from the acquisition apparatus and controls the acquisition apparatus
10 and the administration controller based on that acquired data. Thus the acquisition
protocol can be controlled and changed in response to the actual acquisition
circumstances.




Figure 1 PRIOR ART






Figure 2

Figure 3






(a)




(b)




(c)



(d)



(e)



(f)

Figure 4




Figure 5

THIS PAGE BLANK (USPTO)